Data Presented at the 2014 ASCO Genitourinary Cancers Symposium
IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive results from an important study designed to identify patients with aggressive prostate cancer (PCa). The study, presented at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 – February 1, 2014), confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), that could help to identify patients with aggressive PCa.
“One of the most significant challenges in managing newly diagnosed prostate cancer patients is choosing the best treatment plan. Men diagnosed with GS6 cancer, may be eligible for active surveillance. However, today’s standard 12-core TRUS-guided (transrectal ultrasound) biopsies are susceptible to under-sampling, leaving men at risk for undetected aggressive disease,” noted E. David Crawford, Professor of Surgery, Professor of Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Denver School of Medicine. “These promising data demonstrate that epigenetic testing is not only valuable for the decision on repeat biopsy, but may also yield important prognostic information that could help us to identify men who are at risk for aggressive disease.”
In this study, the prognostic value of the epigenetic status of five genes (GSTP1, APC, RASSF1, RARB and LGALS3) in 84 prostatectomy samples with different GS’s was evaluated. The results of a hierarchical clustering analysis showed that low gene methylation levels were detected in the vast majority of patient samples with GS6 and GS7 (3+4) PCa. In contrast, respectively 81% and 91% of the GS7 (4+3) and GS superior or egual 8 samples fell into the category with intermediate to high methylation levels. These data provide evidence of the potential prognostic value of epigenetically profiling selected genes to identify men with a low versus high risk for aggressive PCa.
“These important study results support our overall strategy of leveraging epigenetics to improve the diagnosis and treatment of prostate cancer patients. We were pleased to see that the data generated with the ConfirmMDx for Prostate Cancer genes, suggest the potential for prognostic utility,” explained Dr. Jan Groen, CEO of MDxHealth. “With this information, we are in a position to explore expansion of the ConfirmMDx indication for use in men diagnosed with GS6 prostate cancer, which may help urologists make more informed treatment decisions.”
Over 975,000 American men are diagnosed with a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores only sample approximately 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is able to detect an epigenetic field effect or ‘halo’ associated with the cancerization process at the DNA level. This “halo” around a cancer lesion can be present despite cells having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure.
MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
|Dr. Jan Groen, CEO||Mike Sinclair||Matt Clawson|
|MDxHealth||Halsin Partners||Allen & Caron, Inc|
|US: +1 949 812 6979||UK: +44 20 7318 2955||US: +1 949 474 4300|
|BE: +32 4 364 20 70||Cell:+44 7968 022075|
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.